Physician profile
John E Nyboer
NPI 1104816115
$7,212.04
in general payments reported to CMS, 2019-2025
43 companies · $560 in 2025
The $560 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $1,049 · 2021: $1,052 · 2022: $853 · 2023: $627 · 2024: $1,378 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,119.81 | 2019-2024 | Proclaim |
| Collegium Pharmaceutical, INC. | $780.05 | 2019-2024 | Belbuca |
| Ipsen Biopharmaceuticals, INC | $726.05 | 2019-2025 | Dysport |
| Merz Pharmaceuticals, LLC | $529.31 | 2021-2025 | Xeomin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.37 | 2019-2025 | Relistor |
| Si-Bone, INC. | $371.14 | 2019-2024 | |
| Abbvie INC. | $369.98 | 2021-2025 | |
| Microtransponder, INC. | $294.74 | 2024 | |
| Allergan, INC. | $284.02 | 2019-2021 | |
| Averitas Pharma INC. | $233.02 | 2023-2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $232.53 | 2019-2024 | Ztlido |
| Ibsa Pharma INC. | $197.86 | 2022-2025 | Tirosint, Licart, Flector |
| Saol Therapeutics INC. | $197.62 | 2020 | |
| Pfizer INC. | $177.19 | 2019-2023 | |
| Horizon Therapeutics Plc | $156.44 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John E Nyboer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.